author-photo

Greg Reed

University of Kansas

24

Papers

48

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (1)
1978TiPA window of opportunity trial of atorvastatin targeting p53 mutant malignancies

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Research Cruise Planning & Management, 15 - 19 October 2018. OTGA Training Course RCPM2018BE.

2018
Show All
- Source
- Cite
- Save
Citations (0)
Repurposing ethacrynic acid for the treatment of bladder cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 5882: Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract P6-11-08: Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)